Monoclonal antibody

This page covers all Monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD38, SARS-CoV-2 virus, tumor necrosis factor-alpha (TNF-alpha).

Targets

CD38 · SARS-CoV-2 virus · tumor necrosis factor-alpha (TNF-alpha) · IL-1β · interleukin-6 receptor · Vascular Endothelial Growth Factor (VEGF) · CD20 antigen on pre-B and mature B-lymphocytes · CD20 · TNF-alpha · PD-1/PD-L1 pathway

Marketed (24)

• Darzalex · Johnson & Johnson · Oncology · 11800
  Daratumumab binds CD38 on tumor cells, inducing apoptosis and immune-mediated lysis via CDC, ADCC, and ADCP.
• Famtozinameran 12 Years of age and older · Pfizer · Infectious Disease · 4367
  Famtozinameran works by targeting the SARS-CoV-2 virus.
• Infliximab [infliximab biosimilar 3] · Pfizer · Oncology · 646
  Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions.
• Canakinumab Injection · Pfizer · 372
  Canakinumab Injection is a monoclonal antibody that targets and neutralizes interleukin-1 beta (IL-1β) to treat inflammatory conditions.
• tocilizumab or sarilumab · Pfizer · Immunology · 116
• Bevacizumab · Roche · Oncology
  Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR.
• Mabthera · Roche · Oncology
  Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC.
• Treatment plan · Fondazione Italiana Linfomi - ETS · Oncology
  Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
• TNF Inhibitor · Pfizer · Immunology
• Pf-06865571 · Pfizer · Oncology
• REZ · Centers for Disease Control and Prevention · Oncology
  REZ is a monoclonal antibody that targets the CD19 protein on B cells.
• Part A: ATM-AVI Single Dose, Cohorts 1-4 · Pfizer · Infectious Disease
• RSVpreF · Pfizer · Infectious Disease
• Rituximab-pvvr · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Oncology
  Rituximab-pvvr is a monoclonal antibody that targets the CD20 antigen on B-lymphocytes, leading to B-cell lysis through mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
• RSVpreF MDV · Pfizer Inc. · Infectious Disease
• Dupilumab therapy · National Medical Research Center for Children's Health, Russian Federation · Immunology
• Anti-Beta Interferon (PF-06823859) · Pfizer · Immunology
• Avelumab (MSB0010718C) · Pfizer · Oncology
• AntiCov-220 · Nguyen Thi Trieu, MD · Infectious disease
  AntiCov-220 is an antibody that targets the SARS-CoV-2 spike protein.
• Stopping dupilumab · University Hospital, Toulouse · Immunology
  Dupilumab is a human monoclonal antibody that binds to the interleukin-4 receptor alpha subunit, blocking the signaling of IL-4 and IL-13, which are key cytokines in type 2 inflammation.
• Anti-OX40 Antibody PF-04518600 · Pfizer · Oncology
• Famtozinameran 5 to 11 Years of age · Pfizer · Infectious Disease
• Hympavzi · Pfizer Inc · Rare Disease
  Hympavzi works by binding to Factor Xa, a protein involved in blood clotting.
• Pf-06823859 · Pfizer · Oncology

Phase 3 pipeline (45)

• TP-03 · Tarsus Pharmaceuticals, Inc. · Ophthalmology
  TP-03 is a monoclonal antibody targeting the CD40 receptor.
• MB-102 DMID · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Oncology
  MB-102 DMID is a monoclonal antibody targeting CD47.
• monoclonal antibody Ch14.18 · National Cancer Institute (NCI) · Oncology
  Ch14.18 is a monoclonal antibody that targets GD2, a disialoganglioside found on the surface of certain cancer cells.
• Trastuzumab IV · Hoffmann-La Roche · Oncology
  Trastuzumab IV works by targeting and binding to the HER2/neu receptor on cancer cells, triggering an immune response and inhibiting cell growth.
• SEL-212 low-dose · Swedish Orphan Biovitrum · Oncology
  SEL-212 is a monoclonal antibody targeting CD19.
• Placebo to omalizumab · Novartis · Immunology
  Omalizumab is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human immunoglobulin E (IgE) with high affinity.
• Prolia® (Denosumab) · Samsung Bioepis Co., Ltd. · Osteoporosis, Bone-related disorders
  Prolia works by binding to RANKL, a protein involved in the formation and activation of osteoclasts, which are cells that break down bone.
• Rituximab IV · Hoffmann-La Roche · Oncology
  Rituximab IV works by targeting and depleting CD20-positive B cells.
• Rabbit Anti-Human Thymocyte Globulin · Dr. Claudia Bösmüller · Immunology
  Rabbit Anti-Human Thymocyte Globulin works by depleting T lymphocytes, thereby reducing the immune response.
• ALXN2220 · Neurimmune AG · Neurology
  ALXN2220 is a monoclonal antibody that targets phosphatidylserine on apoptotic cells to enhance their clearance and reduce neuroinflammation.
• VYD2311-MD · Invivyd, Inc. · Infectious Disease
  VYD2311-MD is a monoclonal antibody that targets the SARS-CoV-2 spike protein.
• Soliris (eculizumab) · Samsung Bioepis Co., Ltd. · Immunology
  Soliris works by inhibiting the complement system by blocking the action of C5.
• anti-CD 25 mAb, Sirolimus, MMF · University of Regensburg · Immunology
  Anti-CD 25 mAb targets and binds to the CD25 receptor on T cells, preventing their activation and proliferation.
• UX003 · Ultragenyx Pharmaceutical Inc · Cardiovascular
  UX003 is a recombinant human monoclonal antibody that targets angiopoietin-like 3 (ANGPTL3) protein.
• efgartigimod administration · Clinique Neuro-Outaouais · Autoimmune diseases
  Efgartigimod is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn) to reduce immunoglobulin G (IgG) levels.
• Antimalarial monoclonal antibodies · Liverpool School of Tropical Medicine · Infectious Disease
  Monoclonal antibodies that target and neutralize malaria parasites or parasite-derived antigens to prevent infection and reduce disease severity.
• isatuximab SAR650984 · Sanofi · Oncology
  Isatuximab is a monoclonal antibody that targets CD38, a protein found on the surface of certain cancer cells.
• monoclonal antibody BEC2 · European Organisation for Research and Treatment of Cancer - EORTC · Oncology
  BEC2 is a monoclonal antibody that targets GD3 ganglioside on tumor cell surfaces to trigger immune-mediated destruction of cancer cells.
• motavizumab (MEDI-524) · MedImmune LLC · Respiratory
  Motavizumab is a monoclonal antibody that targets the respiratory syncytial virus (RSV) F-protein.
• tezepelumab (Arm1&Arm2) · Qilu Pharmaceutical Co., Ltd. · Immunology
  Tezepelumab blocks the activity of thymic stromal lymphopoietin (TSLP), a key cytokine involved in allergic inflammation.
• Trastuzumab/Hyaluronidase-oysk · National Cancer Institute (NCI) · Oncology
  Trastuzumab targets the HER2/neu receptor, while hyaluronidase is an enzyme that helps the drug spread more evenly throughout the body.
• Rituximab (Mabthera) · Shereen Medhat Mohammed Elsayed Nassar · Oncology, Immunology
  Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
• pexelizumab in conjunction with CABG · Alexion Pharmaceuticals, Inc. · Cardiovascular
  Pexelizumab is a monoclonal antibody that inhibits the complement component 5 (C5) to reduce inflammation.
• Synthetic neutralising antibodies · University of Oxford · Infectious Diseases
  Synthetic neutralising antibodies work by binding to and neutralising specific viral proteins, thereby preventing the virus from infecting cells.
• Ocrevus-US · Sandoz · Immunology
  Ocrevus-US is a monoclonal antibody that targets CD20 on B cells.
• Rituxan +CHOP · Shandong New Time Pharmaceutical Co., LTD · Oncology
  Rituxan is a monoclonal antibody that targets and depletes CD20-positive B cells, while CHOP is a chemotherapy regimen that includes cyclophosphamide, doxorubicin, vincristine, and prednisone.
• EG12014 · EirGenix, Inc. · Oncology
  EG12014 is a monoclonal antibody targeting CD19.
• immunomodulatory treatment by rituximab · University Hospital, Bordeaux · Immunology
  Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their depletion and subsequent immunomodulation.
• monoclonal antibodies GD2 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Oncology
  GD2-targeting monoclonal antibodies work by binding to GD2, a glycolipid found on the surface of certain cancer cells, to induce cell death and inhibit tumor growth.
• Rituximab (Arm B) · Ostfold Hospital Trust · Oncology, Immunology
  Rituximab works by targeting and depleting B cells, which are a type of immune system cell involved in the production of antibodies.
• Rituximab (EU) · Amgen · Oncology, Immunology
  Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
• Rituximab Biosimilar · Merck Sharp & Dohme LLC · Oncology
  Rituximab Biosimilar works by targeting and depleting CD20-positive B cells.
• Romosozumab Prefilled Syringe · Karen Klahr Miller, MD · Bone disorders
  Romosozumab Prefilled Syringe is a monoclonal antibody that targets sclerostin to increase bone formation and decrease bone resorption.
• SR-B + Epratuzumab · Charite University, Berlin, Germany · Immunology
  SR-B combined with epratuzumab targets B cell surface antigens to modulate immune response in autoimmune and inflammatory conditions.
• Tositumomab and Iodine I 131 Tositumomab · GlaxoSmithKline · Oncology
  Tositumomab is a monoclonal antibody that targets the CD20 antigen on B cells, leading to their destruction.
• Tixagevimab Cilgavimab · Azienda Ospedaliera Universitaria Integrata Verona · Infectious disease
  Tixagevimab and cilgavimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein, preventing viral entry into host cells.
• Omalizumab for injection · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Immunology
  Omalizumab is a monoclonal antibody that targets the IgE molecule, preventing it from binding to its receptor on mast cells and basophils.
• Maintenance weekly x4 · Fondazione Italiana Linfomi - ETS · Oncology
  This drug targets the CD19 protein on B cells to induce apoptosis.
• optimised rituximab-schedule · Universität des Saarlandes · Oncology, Immunology
  Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
• efgartigimod IV · argenx · Immunology
  Efgartigimod IV is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn), thereby reducing the levels of immunoglobulin G (IgG) in the body.

Phase 2 pipeline (39)

• Cetuximab Radioimmunotherapy · Arbeitsgemeinschaft medikamentoese Tumortherapie · Oncology
  Cetuximab Radioimmunotherapy targets and destroys cancer cells by binding to the epidermal growth factor receptor (EGFR) and delivering a radioactive payload.
• Active JNJ Drug · Chengappa, K.N. Roy, MD · Oncology
  Active JNJ drug is a monoclonal antibody that targets a specific molecular target.
• BAY 94-8862 · Bayer · Infectious disease
  BAY 94-8862 is a monoclonal antibody targeting SARS-CoV-2.
• GL-0817 · Gliknik Inc. · Oncology
  GL-0817 is an anti-CD47 monoclonal antibody.
• Anti-IL8 · Bristol-Myers Squibb · Immunology
  Anti-IL8 binds to interleukin-8 (IL-8), a chemokine involved in inflammation, to reduce its activity.
• Basiliximab Injection · Fort Worth Clinical Sciences Working Group · Immunology
  Basiliximab Injection is a chimeric monoclonal antibody that binds to the alpha chain of the IL-2 receptor (CD25) on the surface of activated T lymphocytes.
• BAX326 · Baxalta now part of Shire · Oncology
  BAX326 is a monoclonal antibody targeting CD19.
• Anti-COVID-19 human immunoglobulin · Lifefactors Zona Franca, SAS · Infectious Diseases
  Anti-COVID-19 human immunoglobulin works by providing pre-formed antibodies to neutralize the SARS-CoV-2 virus.
• Daratumumab, Ixazomib, Dexamethasone · Hellenic Society of Hematology · Oncology
  Daratumumab is a monoclonal antibody that targets CD38.
• CNTO 1275 · Centocor, Inc. · Immunology
  CNTO 1275 is a fully human monoclonal antibody that targets the CD28 receptor.
• ARGX-117 · argenx · Autoimmune diseases
  ARGX-117 is a monoclonal antibody targeting CD70.
• Avastin, Alimta · The Cooper Health System · Oncology
  Avastin (bevacizumab) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis and tumor growth.
• CT-P59 · Celltrion · Infectious Disease
  CT-P59 is a COVID-19 treatment that works by binding to the SARS-CoV-2 spike protein.
• CUCART19 · Chi Kong Li · Infectious Disease
  CUCART19 is a monoclonal antibody targeting the SARS-CoV-2 spike protein.
• CSL346 · CSL Behring · Oncology
  CSL346 is a monoclonal antibody targeting the CD19 protein.
• Anti-IP-10 Antibody · Bristol-Myers Squibb · Immunology
  Anti-IP-10 Antibody works by binding to IP-10, a chemokine involved in the recruitment of immune cells to sites of inflammation.
• BT061 · Biotest · Oncology
  BT061 is a monoclonal antibody targeting CD19.
• EFG PH20 SC · argenx · Neurology
  EFG PH20 SC is a monoclonal antibody targeting ephrin type-A receptor 4 (EphA4).
• AGB101 · AgeneBio · Neurology
  AGB101 is a monoclonal antibody targeting amyloid-beta
• Dinutuximab. Immunotherapy · Fundació Sant Joan de Déu · Oncology
  Monoclonal antibody targeting GD2
• DRM02 · Dermira, Inc. · Immunology
  DRM02 is a monoclonal antibody that targets CD40L.
• BIIB014 · Biogen · Oncology
  BIIB014 is a monoclonal antibody targeting CD20.
• Chemotherapy-Rituximab combination · Northern Italy Leukemia Group · Oncology
  Rituximab targets CD20 on B cells
• BRII-296 · Brii Biosciences Limited · Infectious disease
  BRII-296 is a monoclonal antibody that targets the SARS-CoV-2 spike protein.
• BT086 · Biotest · Oncology
  BT086 is a monoclonal antibody targeting CD19.
• CNTO 136 · Centocor, Inc. · Immunology
  CNTO 136 is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), which are involved in inflammatory responses.
• AGMB-129 · Agomab Spain S.L. · Oncology
  AGMB-129 is an anti-CD47 monoclonal antibody.
• ACH-0144471 · Alexion Pharmaceuticals, Inc. · Autoimmune diseases
  ACH-0144471 is a monoclonal antibody targeting the CD40 receptor.
• Bezlotoxumab Injection [Zinplava] · Fundacion SEIMC-GESIDA · Infectious Disease
  Inhibits Clostridioides difficile toxin
• ESCALATED BEACOPP · Ospedale Santa Croce-Carle Cuneo · Oncology
  Beacopan is a monoclonal antibody that targets CD137, a member of the tumor necrosis factor receptor superfamily.
• Daratumumab with dexamethasone · Hellenic Society of Hematology · Oncology
  Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells.
• CCX354-C · Amgen · Inflammatory diseases
  CCX354-C is a monoclonal antibody that targets the IL-1 receptor antagonist (IL-1RA) to prevent IL-1 mediated inflammation.
• Erenumab Auto-Injector · Clinique des Céphalées de Montréal · Neurology
  Erenumab is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor.
• ARGX-119 IV · argenx · Autoimmune diseases
  ARGX-119 IV is a monoclonal antibody targeting CD70.
• BRII-835 · Brii Biosciences Limited · Infectious disease
  BRII-835 is a monoclonal antibody that targets the SARS-CoV-2 spike protein.
• Campath Purged Non-myeloablative ASCT · David Rizzieri, MD · Oncology
  Campath (Alemtuzumab) is a monoclonal antibody that targets CD52, a protein found on the surface of mature lymphocytes.
• CERC-301 · Avalo Therapeutics, Inc. · Autoimmune diseases, Oncology
  CERC-301 is a monoclonal antibody targeting CD28 to modulate T-cell activation.
• Efgartigimod IV or Efgartigimod PH20 SC · argenx · Neurology
  Monoclonal antibody targeting muscle relaxant proteins
• Disitamab Vedotin Injection （18 weeks） · RemeGen Co., Ltd. · Oncology
  Anti-CD6 monoclonal antibody

Phase 1 pipeline (6)

• Anti-CD38 Monoclonal Antibody · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Oncology
  Monoclonal antibody targeting CD38
• ARGX-213 · argenx · Immunology
  Monoclonal antibody targeting CD20
• ARGX-113 with rHuPH20 · argenx · Immunology
  Monoclonal antibody targeting the neonatal Fc receptor (FcRn)
• Anti-RANKL Monoclonal Antibody · Shanghai JMT-Bio Inc. · Osteoporosis
  Inhibits RANKL
• Alemtuzumab i.v. · German CLL Study Group · Oncology
  CD52 is a surface protein on mature lymphocytes; Alemtuzumab binds to CD52 and induces cell death.
• Alemtuzumab s.c. · German CLL Study Group · Oncology
  CD52-targeting monoclonal antibody